TNF Receptor-Associated Periodic Syndrome (TRAPS)
A hereditary autoinflammatory disorder causing recurrent fever episodes and systemic inflammation, driven by mutations in the TNFRSF1A gene.
- Biologic therapies available
- Genetic testing confirms diagnosis
- Manageable with specialist care
- Most Common In
- Any age; autosomal dominant inheritance
- Typical Pattern
- Recurrent fever episodes lasting days to weeks
- Affected Gene
- TNFRSF1A
- Advanced Therapies
- IL-1 and IL-6 pathway biologics
What Is TRAPS?
TNF Receptor-Associated Periodic Syndrome (TRAPS) is a hereditary autoinflammatory disorder caused by mutations in the TNFRSF1A gene, which encodes the type 1 tumor necrosis factor receptor. These mutations disrupt normal receptor function and trigger excessive innate immune activation, leading to recurrent episodes of fever and inflammation that can affect the skin, joints, muscles, and eyes.
Unlike infections, TRAPS episodes are driven by dysregulated inflammatory signaling rather than a pathogen, and they typically recur unpredictably over a person's lifetime, sometimes from childhood onward. Episodes can last days to several weeks and are often accompanied by significant fatigue and discomfort between flares in some patients.
TRAPS is inherited in an autosomal dominant pattern, meaning a single altered copy of TNFRSF1A is enough to cause disease, though severity and exact symptoms can vary considerably even within the same family.
Clinical Variants
TRAPS is classified by the specific TNFRSF1A variant involved, which can influence disease severity.
Symptoms and Warning Signs
TRAPS typically presents as recurring episodes of fever accompanied by a range of inflammatory symptoms.
Causes and Risk Factors
TRAPS is a genetic disorder; it is not caused by infection, diet, or lifestyle factors, though episodes can sometimes be triggered by stress or minor illness.
Diagnosis and Investigations
Diagnosis of TRAPS combines clinical pattern recognition, inflammatory marker testing, and genetic confirmation.
Disease Severity Stratification
TRAPS is not formally staged, but clinicians classify patients by flare frequency and inflammatory burden to guide treatment intensity.
Standard Treatment Approach
Treatment for TRAPS aims to control acute flares, reduce flare frequency, and prevent long-term complications such as amyloidosis.
Advanced and Emerging Treatment Options
Biologic therapies targeting specific inflammatory pathways have transformed management of TRAPS for patients with frequent or severe flares.
Immunotherapy
IL-1 inhibitors (e.g. anakinra, canakinumab)
Block interleukin-1 signaling, which plays a central role in TRAPS inflammation, often substantially reducing flare frequency and severity.
Immunotherapy
IL-6 inhibitors (e.g. tocilizumab)
An alternative biologic approach for patients with inadequate response to IL-1 blockade.
Precision Medicine
Genotype-guided treatment selection
Emerging research is exploring whether specific TNFRSF1A variants predict response to particular biologic classes.
Biomarkers and Precision Testing
Inflammatory and genetic markers guide both diagnosis and ongoing monitoring in TRAPS.
When a Second Opinion May Be Important
Because TRAPS can mimic other periodic fever syndromes and infections, specialist input is often valuable.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With appropriate biologic therapy, most people with TRAPS can achieve good control of flares and a substantially reduced risk of long-term complications.
Supportive Care and Living With TRAPS
Living with TRAPS involves both medical management and practical strategies to cope with unpredictable flares.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with TRAPS connect with specialists experienced in autoinflammatory diseases, coordinate medical report review, and explore access to biologic therapies.
Get a free case reviewFrequently Asked Questions
TRAPS is a hereditary autoinflammatory disorder caused by mutations in the TNFRSF1A gene, leading to recurrent episodes of fever and systemic inflammation.
Common early signs include recurrent fever, migratory muscle pain, skin rash, and abdominal discomfort occurring in episodes.
No โ they are related autoinflammatory conditions caused by different genes, with overlapping but distinct symptom patterns and treatment responses.
Treatment ranges from NSAIDs for mild disease to IL-1 or IL-6 pathway biologic therapy for patients with frequent or severe flares.
Yes โ TRAPS is inherited in an autosomal dominant pattern, meaning a single altered gene copy can cause disease, though severity varies.
Long-standing untreated inflammation can rarely lead to AA amyloidosis affecting the kidneys, which is why regular monitoring is recommended.
There is no cure, but biologic therapies can effectively control flares and reduce long-term complications for most patients.
Diagnosis combines a characteristic fever pattern, elevated inflammatory markers during flares, and confirmatory TNFRSF1A genetic testing.
Yes โ TRAPS can present in childhood or adulthood, with onset age and severity varying between individuals and families.
Yes. CancerFax can help coordinate medical report review, connect patients with specialists experienced in autoinflammatory diseases, support second opinion requests, and facilitate access to biologic therapies, including cross-border coordination when needed.
Get Expert Guidance on TRAPS Management
Our team can help you connect with specialists experienced in autoinflammatory diseases for diagnosis confirmation and treatment planning.